(JANX) Janux Therapeutics - Ratings and Ratios
T-Cell Redirectors, Prodrug Masks
JANX EPS (Earnings per Share)
JANX Revenue
Description: JANX Janux Therapeutics
Janux Therapeutics Inc (NASDAQ:JANX) is a biotechnology company listed on the NASDAQ stock exchange. The companys stock is classified under the GICS Sub Industry: Biotechnology, indicating its primary focus on developing and commercializing biotechnological products or therapies.
From a financial perspective, Janux Therapeutics has a market capitalization of approximately $1.34 billion, suggesting a significant presence in the biotechnology sector. The absence of a price-to-earnings (P/E) ratio, both current and forward, implies that the company is not yet profitable, which is common for companies in the biotechnology industry that are often in the development phase. The return on equity (RoE) is negative at -9.29%, indicating that the company is currently not generating profits from shareholder equity.
To assess the viability and potential of Janux Therapeutics, key performance indicators (KPIs) such as research and development (R&D) expenditure, pipeline progress, and cash burn rate are crucial. The companys ability to advance its pipeline, achieve milestones, and eventually generate revenue will be critical drivers of its stock performance. Additionally, the overall demand for its products or therapies, competition in the biotechnology space, and the regulatory environment will significantly impact its financials and stock price.
Economic drivers for Janux Therapeutics include the growing demand for innovative biotechnological treatments, advancements in medical technology, and the overall performance of the biotechnology sector. The companys beta of 2.852 indicates that its stock price is highly volatile compared to the broader market, suggesting a higher risk profile. Investors should closely monitor the companys progress in clinical trials, partnerships, and regulatory approvals, as these factors will be key determinants of its future success and stock performance.
Investors and analysts should also consider the companys cash position, burn rate, and funding requirements to assess its ability to continue operations and invest in R&D. The biotechnology industry is highly competitive and capital-intensive, making it essential for Janux Therapeutics to manage its resources effectively and make strategic decisions to drive growth and profitability.
JANX Stock Overview
| Market Cap in USD | 1,385m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-06-11 |
JANX Stock Ratings
| Growth Rating | -2.19% |
| Fundamental | 24.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -59.2% |
| Analyst Rating | 4.77 of 5 |
JANX Dividends
Currently no dividends paidJANX Growth Ratios
| Growth Correlation 3m | -3.1% |
| Growth Correlation 12m | -89.2% |
| Growth Correlation 5y | 39% |
| CAGR 5y | 23.77% |
| CAGR/Max DD 3y | 0.32 |
| CAGR/Mean DD 3y | 0.62 |
| Sharpe Ratio 12m | -1.78 |
| Alpha | -56.05 |
| Beta | 0.274 |
| Volatility | 71.44% |
| Current Volume | 487.2k |
| Average Volume 20d | 528k |
| Stop Loss | 22.5 (-6.4%) |
| Signal | -1.04 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-105.6m TTM) > 0 and > 6% of Revenue (6% = -484.4k TTM) |
| FCFTA -0.04 (>2.0%) and ΔFCFTA 3.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -12.2k% (prev 4300 %; Δ -16.5kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.06 (>3.0%) and CFO -59.8m > Net Income -105.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 47.03 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (61.9m) change vs 12m ago 13.68% (target <= -2.0% for YES) |
| Gross Margin 125.8% (prev 86.32%; Δ 39.47pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover -0.94% (prev 2.19%; Δ -3.12pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -2.80
| (A) 0.95 = (Total Current Assets 1.01b - Total Current Liabilities 21.4m) / Total Assets 1.03b |
| (B) -0.29 = Retained Earnings (Balance) -295.1m / Total Assets 1.03b |
| (C) -0.12 = EBIT TTM -100.3m / Avg Total Assets 861.8m |
| (D) -6.99 = Book Value of Equity -291.3m / Total Liabilities 41.7m |
| Total Rating: -2.80 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 24.43
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -10.75% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.02 = 2.50 |
| 5. Debt/Ebitda -0.22 = -2.50 |
| 6. ROIC - WACC -17.99% = -12.50 |
| 7. RoE -11.48% = -1.91 |
| 8. Rev. Trend -53.62% = -2.68 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend -19.01% = -0.48 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of JANX shares?
Over the past week, the price has changed by -3.06%, over one month by -3.68%, over three months by +1.86% and over the past year by -51.79%.
Is Janux Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of JANX is around 21.20 USD . This means that JANX is currently overvalued and has a potential downside of -11.85%.
Is JANX a buy, sell or hold?
- Strong Buy: 11
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the JANX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 82.5 | 242.9% |
| Analysts Target Price | 82.5 | 242.9% |
| ValueRay Target Price | 23.3 | -3% |
Last update: 2025-09-05 04:48
JANX Fundamental Data Overview
CCE Cash And Equivalents = 996.0m USD (Cash And Short Term Investments, last quarter)
P/S = 3153.903
P/B = 1.3978
Beta = 2.852
Revenue TTM = -8.07m USD
EBIT TTM = -100.3m USD
EBITDA TTM = -98.7m USD
Long Term Debt = 20.3m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.87m USD (from shortTermDebt, last quarter)
Debt = 22.2m USD (Calculated: Short Term 1.87m + Long Term 20.3m)
Net Debt = -30.3m USD (from netDebt column, last quarter)
Enterprise Value = 410.7m USD (1.38b + Debt 22.2m - CCE 996.0m)
Interest Coverage Ratio = unknown (Ebit TTM -100.3m / Interest Expense TTM 0.0)
FCF Yield = -10.75% (FCF TTM -44.2m / Enterprise Value 410.7m)
FCF Margin = -547.2% (FCF TTM -44.2m / Revenue TTM -8.07m)
Net Margin = -1309 % (Net Income TTM -105.6m / Revenue TTM -8.07m)
Gross Margin = -125.8% ((Revenue TTM -8.07m - Cost of Revenue TTM 2.08m) / Revenue TTM)
Tobins Q-Ratio = -1.41 (set to none) (Enterprise Value 410.7m / Book Value Of Equity -291.3m)
Interest Expense / Debt = 14.76% (Interest Expense 3.27m / Debt 22.2m)
Taxrate = 21.0% (US default)
NOPAT = -100.3m (EBIT -100.3m, no tax applied on loss)
Current Ratio = 47.03 (Total Current Assets 1.01b / Total Current Liabilities 21.4m)
Debt / Equity = 0.02 (Debt 22.2m / last Quarter total Stockholder Equity 990.5m)
Debt / EBITDA = -0.22 (Net Debt -30.3m / EBITDA -98.7m)
Debt / FCF = -0.50 (Debt 22.2m / FCF TTM -44.2m)
Total Stockholder Equity = 920.5m (last 4 quarters mean)
RoA = -10.23% (Net Income -105.6m, Total Assets 1.03b )
RoE = -11.48% (Net Income TTM -105.6m / Total Stockholder Equity 920.5m)
RoCE = -10.66% (Ebit -100.3m / (Equity 920.5m + L.T.Debt 20.3m))
RoIC = -10.89% (NOPAT -100.3m / Invested Capital 920.5m)
WACC = 7.09% (E(1.38b)/V(1.41b) * Re(7.02%)) + (D(22.2m)/V(1.41b) * Rd(14.76%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 3.70%
Discount Rate = 7.02% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -44.2m)
Revenue Correlation: -53.62 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: -157.6
EPS Correlation: -19.01 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -87.97
Additional Sources for JANX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle